Compare ESQ & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ESQ | AKBA |
|---|---|---|
| Founded | 2006 | 2007 |
| Country | United States | United States |
| Employees | 151 | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 910.9M | 729.1M |
| IPO Year | 2017 | 2014 |
| Metric | ESQ | AKBA |
|---|---|---|
| Price | $108.17 | $1.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $120.33 | $5.75 |
| AVG Volume (30 Days) | 71.3K | ★ 2.6M |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.76% | N/A |
| EPS Growth | 14.20 | ★ 93.94 |
| EPS | ★ 5.87 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $28.65 | N/A |
| Revenue Next Year | $4.95 | N/A |
| P/E Ratio | $17.97 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $69.14 | $1.14 |
| 52 Week High | $119.86 | $4.08 |
| Indicator | ESQ | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 54.55 | 54.11 |
| Support Level | $91.62 | $1.30 |
| Resistance Level | $112.17 | $1.52 |
| Average True Range (ATR) | 3.81 | 0.07 |
| MACD | 0.66 | 0.01 |
| Stochastic Oscillator | 65.46 | 61.84 |
Esquire Financial Holdings Inc is a financial holding company operating as a full service commercial bank. It serves the financial needs of the litigation industry and small businesses nationally, as well as commercial and retail customers in the New York metropolitan area. The bank offers tailored financial and payment processing solutions to the litigation community and their clients as well as dynamic and flexible payment processing solutions to small business owners. It operates in one operating segment, that of community banking.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.